The rebrand creates a platform that is expected enhance the way life sciences companies bring their therapies to market.

As this medical approach continues to become more widely adopted, the industry must adapt to help provide precise, compliant, ...

In the final part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, describes best practices for balancing long-term pipeline sustainability with ...

Pharmaceutical Commerce connects biopharma executives to insights on business processes, technologies, and strategies for taking approved drugs to market.

Addressing drug shortages requires the industry to embrace innovative advanced manufacturing processes underpinned by ...

Bruce Leuchter, CEO, Neurvati, discusses the indispensable role of patient advocates—particularly in rare and serious disease drug development—in shaping trial design, site selection, and regulatory ...

In an interview with Applied Clinical Trials, Michel van Harten, MD, CEO of myTomorrows, explained how AI can help address clinical trial diversity and access challenges by reducing physician workload ...

In a Q&A with Pharma Commerce, Kurt Lunkwitz, ProRx Pharma’s COO, uncovers the stringent requirements that 503B outsourcing facilities must abide by under the Drug Quality and Security Act, while also ...

In the fourth part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, ...

In a recent interview with Applied Clinical Trials, Michel van Harten, MD, CEO of myTomorrows, discussed how AI is transforming clinical trials by reducing costs, accelerating timelines, and enhancing ...